Is clopidogrel superior to aspirin in secondary prevention of vascular disease?
AUTOR(ES)
Algra, Ale
FONTE
BioMed Central
RESUMO
The cornerstone in clinical evidence of the relative efficacy of thienopyridines (clopidogrel, ticlopidine) versus aspirin in the secondary prevention of vascular disease is the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events trial. This trial showed a modest benefit in the reduction of vascular events by clopidogrel. The results differed according to qualifying disorder: myocardial infarction, -3.7%; ischaemic stroke, +7.3%; and peripheral arterial disease, +23.8% (P = 0.042). Similar results were found for ticlopidine after brain ischaemia. The safety of clopidogrel appears to be similar to that of aspirin and better than that of ticlopidine. However, the recent report of thrombotic thrombocytopenic purpura in association with clopidogrel causes concern.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=59615Documentos Relacionados
- Is Mycoplasma pneumoniae Associated with Vascular Disease?
- Who are the proteolytic culprits in vascular disease?
- Secondary prevention of heart disease with statins: Study seems to be about tertiary rather than secondary prevention
- Aspirin + PPI is safer than clopidogrel if patient has history of GI bleeding
- AGEing growth factors: a role in diabetic vascular disease?
